CLL 17

CLL17: A phase 3 multicentre, randomized, prospective, open-label trial of ibrutinib monotherapy versus fixed-duration venetoclax plus obinutuzumab versus fixed-duration venetoclax plus ibrutinib in patients with previously untreated chronic lymphocytic leukaemia (CLL)